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Studies on Protein Inhibitors of the Extension of
Alzhiemer's Fibrils (AP1-40) using a Sensitive
Streptavidin-Europium Assay

Alan J. Greene Jr.
Mentor and P.I. : Dr. Ronald Wetzel Ph.D
Department of Biochemistry and Cellular and Molecular Biology
University of Tenneesse, Knoxville, TN , 37920

Abstract:

Amyloid plaques, comprised mainly of a fibrillar form of amyloid ~ protein (A~),
are a defining pathological feature of Alzheimer' s disease (AD). Therefore, studies on
Alzheimer's disease have concentrated on obtaining potent protein and peptide inhibitors
of A~ fibrillogeneses . We have explored the inhibitory activities of BSA, HSA, and
ovarian ovalbumin on the rate of fibril extension in-vitro using a very sensitive microplate
assay.

In contrast to other extension assays that use high concentrations of A~ (/lM

range) we can measure the extension of fibrils down to the sub-fmol range using
physiological concentrations of A~ (nM range) . Sonicating

A~

fibrils greatly increases the

fibril' s ability to seed the extension reaction. This enhancement of seeding ability is most
likely due to an increase in the number of fibril growing ends that are accessible to

A~

monomer binding.
All the proteins in our inhibition studies, even the ovarian ovalbumin, have similar
inhibitory potencies. For example, similar concentrations of the inhibitors (2J.1.M) inhibit
the rate of fibril extension by 25-30%. This suggests that many polypeptides are be able
to inhibit fibril extension. To test whether the proteins require a native folded structure to
inhibit fibril extension, the inhibitors were denatured by breaking their disulfide bonds
using reduction and alkylation. Surprisingly, we found that these modifications enhanced
their inhibitory potencies by 2 fold in most cases.

An IC so value of 0.18/lM was

determined for modified HSA. These results suggest that the protein' s native structure
plays little to no role in the inhibition of fibril extension.

Introduction:

Alzheimer's disease (AD) is a progressive senile dementia'that effects a
significant amount of the elderly [1], Amyloid plaques, hard waxy deposits
consisting of proteins and polysaccharide, are the defining pathological feature
of the AD brain [2]. The major constituent of amyloid is a hydrophobic 30-43
amino acid peptide, p-amyloid (AP) [3]. AP is a cleavage product of a large
trans-membrane protein, amyloid precursor protein , that is encoded by the APP
gene [4] .
Similar concentrations of AI3 (nM) have been observed in the plasma and
cerebral spinal fluid (CSF) of both normal and AD patients [5]. Also, AI3 is
constitutively produced by cells in culture [6]. However, several studies show
that the accumulation of insoluble rather than soluble AP is linked to AD. For
example, the transition of AI3 from soluble to insoluble peptide is associated with
the onset of cellular toxicity [4]. In addition, overproduction of the peptide in
transgenic mice leads to both Significant AP deposition and neuronal toxicity [7].
Therefore, the suppression or prevention of the transition of AP from monomeric
to a toxic insoluble aggregate has emerged as a goal in the development of
therapy for AD [3].
The majority of assays that are currently used to measure the inhibition of
fibril growth by inhibitors suffers a major drawback. These assays require high
concentrations of AI3 (in the 11M range) that are significantly .greater than the
physiological concentration of AI3 (in the nM range) [5]. One assay uses
physiological concentrations of AI3 , but it also uses radio-labeled AI3 [8] . In

contrast, we have studied the inhibitory potencies of native and denatured BSA,
HSA, and Dvalbumin using a sensitive microplate assay that uses physiological
concentrations of biotinylated

Ap. The rate of fibril extension is monitored by

measuring time-resolved fluorescence of europium. The europium probe is
attached to biotinylated

AP using streptavidin. This method eliminates the

damaging ionizing radiation associated with radio-labeled

Ap.

Using the microplate assay we screened several proteins for any
inhibitory activity on

AP fibril

extension. All of the proteins tested have similar

inhibitory potencies. To determine if the proteins require a native folded
structure to inhibit fibril extension the inhibitory proteins were modified by
reduction and alkylation. We found that these modifications enhances the
inhibitory potency of the proteins. The results suggest that the native structure
of the protein plays little to no role in the protein's inhibitory activity of fibril
extension.

Methods and Materials:
Materials: A~ fibrils and biotinylated A~ were prepared by others using

unconjuqated and cysteine (N-terminal) conjugated A~ peptides obtained from
Quality Controlled Biochemicals (Hopkinton, MA).

Essentially fat free bovine

serum albumin (BSA) , human serum albumin (HSA) , and ovarian ovalbumin
were obtained from sigma. All chemicals were of analytical grade.
Preparation of sonicated fibrils and coating of the micro titer plate: To A~

fibrils (a gift from B. O'Nualiian; UT Medical Center, Knoxville TN) in phosphate
buffered saline (PBS) and O.OS% sodium azide, at pH 7.4 (standard buffer) , a
solution of 1mM dithiothreiroJ and O.SmM EDTA was added. The fibril solution
was sonicated on ice for 0-2S0 seconds (30s burst) using a Tekmar sonicator.
Aliquots (1 OOIlL) of 0.2Sllg/mL

A~

fibrils in standard buffer were pipetted into the

wells of a high binding microtiter plate (Corning EINRIA plate) . Control wells
were not coated with fibrils . The plate was then sealed, and allowed to incubate
at room temperature for 2.S days. After incubation the plate was washed twice
with a wash buffer (PBS and 0.01 % tween). Wells of the micr.otiter plate were
blocked with 200llL of PBS containing 0.3% gelatin, sealed and incubated for 2
hours at 37°C. The plate was then washed with washing buffer, and 1OOIlL of
standard solution was placed in each wel l. The plate was seated, and stored for
up to two weeks at 4°C (Figure 1).
Extension Assay: AJiquots (100IlL) of SnM biotinylated A~ monomer (a

gift from R. Wetzel UT Medical Center, Knoxville, TN) in standard buffer with or
without inhibitor present (0.2-30IlM) was added to specific control and sample

wells of the microplate over a period of 6h at 37°C (Figure 1). Experimental
data was measured in triplicate. After the final time point, the plate was washed
twice and 100llL of O.1llg/ml strepavidin-europium complex (Wallac corp.) was
added to each well. The plate was sealed and incubated for 1h at room
temperature. After 1 hour the plate was washed three times and 100llL of
enhancement solution (Wallac corp.) was added to each well for 5-7min, at room
temperature (Figure 1). Time resolved Europium fluorescence was measured
using a Wallac 1420 Victo~ Multilabel Counter. The rates of extension were
then calculated by plotting the amount of AI3 that deposited onto the fibril seed
(corrected using control readings) and obtaining the initial rate of the extension
reaction directly from the slope of the straight line that best fits the data.
Fluorimetry: Protein and ANS fluorescence were monitored at room

temperature using a Perkins Elmer Luminescence Spectrometer LS50B.
Readings were carried out using 11lM protein in PBS, with or without 21lM ANS,
pH 7.4. The protein and ANS fluorescence were measured with excitation at
280nm and 350nm respectively. The emission and excitation slits were both set
at 5nm for protein fluorescence measurements. Slits of 2.5nm and 5nm were
used when measuring ANS fluorescence.
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Figure 1. Schematic Representation of the Af3 Fibril Extension Microplate
Assay. Step 1: The microplate is coated with sonicated synthetic fibrils then bl()(;ked
with gelatin. Step 2: A biotinylated A~ monome-r solution is added and aJIowed in
incubate with or without inhibitor at intervals for up to 6 h. Step 3: The StrepavidinEuropium complex is added to the plate and allowed to incubate at room temperature
for 1 hour. Between each step the wells were washed. For a more detailed
explanation of the experiment see Methods and Materials .
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Figure 2. Determination of the Initial Rate of Af3 Fibril Extension. The reaction was
monitored using the microplate assay with each well containing 25ngllOOl-tL of sonicated fibrils
and 5nM biotinylated A~ monomer with no inhibitor present at 37°C for 0-6 hours as is described
in the Methods and Materials.
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Figure 3. Effect of Sonication on Initial Fibril Extension. The reaction was monitored using
the microplate assay with each well 25ngllOO!JL of fibrils and 5nM biotinylated AP monomer at 37Co
for 0-6 hours.
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Figure 4. The Effects of Modified HSA on the Rate of Af3 Fibril Extension. The reaction
was monitored at 37Co as is described in Figure 3 and as described in the Methods and Materials.

Table I Comparison of the Intrinsic and Extrinsic Fluorescence Properties
of Native and Modified Protein Inhibitors of A~ Fibril Extension. Protein and
ANS fluorescence wavelength scans were carried out with excitation at 280nm and 396nm respectively.
The excitation and emission slits used were 5nm and lOnm respectively. Each fluorescence reading was
. at room temperature as IS
. descn'bed m
' M et110ds andMatena
. 1s.
. d out WIt
. hIM
carne
!.I. of. protem

Protein

Protein Fluorescence
/, max
(nm)

ANS Fluorescence

Yield
(arbitrary units)

/, max
(nm )

Yield
(arbitrary units)

BSA

347

715

475

475

Modified BSA

334

704

475

280

Ovalbumin

337

377

482

74

337 .

628

474

278

HSA

341

153

476

270

Modified HSA

324

155

476

193

Modified Ovalbumin

Table II Comparison of the Abilities of Native and Modified Proteins to
Inhibit the Rate of AJ3 Fibril Extension. The percentages of inhibition were detennined by
comparing the initial rate of fibril extension with and without an inhibitor present for example Figures I
and 4. The initial rate offibril extension was monitored using the microplate assay as is described in
Methods and Materials.

Inhibitor Protein

Inhibition
(%)

BSA

26.8

Modified BSA

51.3

Ovalbumin

30.1

Modified Ovalbumin

38.8

HSA

25.9

Modified HSA

40.7
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Figure 5. Determination of the IC so Value for the Inhibition of the Rate of AI3 Fibril Extension
by Modified HSA. The percentage inhibition of the reaction by modified HSA was calculated using
values for the il1itial rate of the reaction as is described in Figures 1,4 and Methods and Materials.
All le50 ofO . 18~ was determined for Modified HSA.

Results:
The time resolved fluorescence microplate assay that was used to
monitor the extension of AP fibrils is very sensitive. This sensitivity is because of
the high fluorescence of the probe (Europium) and because the fluorescence of
the probe is measured after a brief waiting period that allows the background
fluorescence to decay and therefore be reduced. In contrast, the use of real
time fluorescence to monitor the reaction can often be limited by background
noise.

Using the microplate assay, we can measure the deposition of AJ3 onto

A13 fibrils down to the sub fmol

range (Figure 2). The initial rate of fibril

1

extension (0.3047 fmol h- ) with physiolgical concentrations (nM) of AJ3 [5] is
reproducibly linear up to six hours (Figure 2). The signal for the deposition of

A13 monomer at onto fibrils at a sub fmol

range is consistently at least 3 fold

greater than the signal obtained for control wells that contain no fibril seed (data
not shown).
The sonication of AP fibrils is known to increase the potency as a seed in
fibril extension reactions [9]. Therefore, as expected sonication of the

A13 fibrils

up to the sonication time (150 s) that we use as our standard condition in our
assay increased the rate of the extension reaction (Figure 3). In contrast,
sonication for greater than 150 seconds causes the rate of the reaction to
decrease by about 20%. Interestingly, no rate of fibril extension was monitored
when the fibrils were unsonicated (Figure 3).
The extension assay is a potentially powerful tool to screen the abilities of
protein to inhibit fibril extension at physiological concentrations of A13·

Therefore, we have screened the abilities of proteins that are known to inhibit
fibril formation (BSA,HSA) and a protein , ovarian ovalbumin , that is not known to
inhibit the reaction. All of the proteins even the ovarian ovalbumin similarly
inhibited the rate of fibril extension (Figures 4&5; Table I). The effects of
denaturing (modifying) the inhibitors ,by breaking their disulfide bridges, on their
activities was tested using their reduced and alkylated forms ( A gift from B.
Q'Nualiain; UT Medical Center, Knoxville TN). Surprisingly, modification of the
proteins improves their inhibitory abilities (Figure 4; Table I). For example there
are 2 fold and 3.5 fold decrease in the rate of fibril extension in the prescence of
0 . 2~M

and

30~M

modified HSA (Figure 4).

To confirm the modification of the protein inhibitors their intrinsic and
extrinsic fluorescence properties were measured. Modification of the proteins
significantly affects intrinsic and extrinsic fluorescent properties (Table II). For
protein fluorescence , modification of the albumins results in a blue shift of their
maximum wavelength emissions by 13-17nm respectively (Table I). ANS
fluorescence is used for studying the hydrophobic binding sites on the proteins
[10,11]. The ANS fluorescence yield for modified albumins is about half that of

the native proteins (Table II). Modification of ovalbumjn results in about a 2 fold
and 4 fold increases in protein and ANS fluorescence respectively (Table II).
An IC50 value is defined as the concentration of inhibitor that gives 50% of
its total inhibition potency. An IC 50 value of 0 . 18~M was determined for the
inhibitory activity of modified HSA (Figure 5). None of the proteins tested , either
in the native or the modified forms were able to inhibit fibril extension 100%.

Discussion:
The microplate extension assay (developed by R. Wetzel ; UT Medical
Center, Knoxville , TN) that was used to screen protein inhibitors is a very
sensitive assay that cam measure fibril extension down to the sub-fmollevel with
minimum background noise. This microplate assay is based on an fibril
extension assay [81 that uses radio-labeled Af3 which requires considerable care,
and is unstable, producing damaging ionizing radiation . In contrast, our assay
uses biotinylated Af3 wh ich is not toxic and relatively cheap. The results of our
studies show that the extension assay is amenable to high-throughput screening
for the identification of Af3 deposition inhibitors using physiological
concentrations of Af3.
The enhanced seed potencies of sonicated fibrils relative to unsonicated
has previously been described by Jarrett and Landsbury [9]. Sonication of fibrils
is likely to increase the available growing ends for the deposition of Af3
monomer. In contrast, the decline in the fibrils abil ity to undergo extension after
150s is interesting. This reduction in seed potency by repeated sonication is
evidently because of effects on the higher order structure of the fibril. In this
regard , studies in our lab (B. O'Nualiian) confirm that sonication of fibrils for long
periods results in a reduction in their abi lities to interact with Thioflavin-T, a
fluorescent die that bind specifically to amyloid.
The inhibitory activities of all the proteins tested suggest that many
polypeptides can inhibit fibril extension . Yet the mechanism of inhibition remains
unknown. However, information can be drawn from the protein screenings.

Proteins exist in both native and non-native states. All of the native proteins
screened have inhibitory activity. However, in all cases there was an increase in
inhibitory potency with the modification of the proteins, where there are no native
structures present. One hypothesis is that the three dimensional structure of the
native protein plays little to no role in the inhibition of fibril extension. Future
studies could concentrate on the inhibitory mechanism of the modified proteins.
Conditions that favor the non-native states of the inhibitors such as denaturants
and temperature could be used to investigate our hypothesis.

References:

1. Hardy, J. and Allsop, D. (1993) Trends Pharmacol. Sci. 12, 383-388.
2. Lansbury, P.T. , Jr. (1996) Acc. Chem.Res. 29, 317-321.
3. Esler, W.P., Stimson, E.R , Ghilardi, J.R , Felix, AM., and Maggio, J.E.
(1997) Nature Biotechnology 15, 258-262.
4. Selkoe, D.J. (1994) J. Neurapathol. Exp. Neural. 53, 438-447.
5. Seubert, P., Vigo-Pelfrey, C., Esch, F. , Lee, M., Dovey, H., and Davis, D., et
al. (1992) Nature 359, 317-322.
6. Haass, C., Schlossmacher, M.G., Hung, AY. , Vigo-Pelfrey, C., Mellon, A ,
and Ostaszewski, B.L. , et al. (1992) Nature 359, 322-325
7. Games, D. , Adams, D., Alessandrini , R, Barbour, R , Berthelette, P. , and
Blackwell, C., et al. (1995) Nature 373, 523-527.
8. Maggio, J.E. , Stimson, E.R , Ghilardi , J.R , Allen, C.J. , Dahl, C.E. , and
Whitcomb, D.C. , et al. (1992) Prac. Natl. Acad. Sci. USA. 15, 5462-5466.
9. Jarrett, J.T. and Lansbury, P.T. Jr. (1992) Biochemistry 31 , 12345-52.
10. Brand, L. and Gohlke, J.R (1972) Annu. Rev. Biochem. 41 , 843-868.
11 . Kella, N.K. , etal. (1984) J. Bioi. Chern. 259, 4777-4781 .

